Can your own stem cells repair heart attack damage?
NCT ID NCT01652209
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether injecting a patient's own bone marrow stem cells into the heart's arteries could improve heart function after a heart attack. 90 adults with reduced heart pumping ability were randomly assigned to receive either stem cells plus standard care or standard care alone. The main goal was to see if the stem cell group had better heart function after 13 months.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Autologous bone marrow derived mesenchymal stem cells (Hearticellgram-AMI)
- What this could lead to
- If successful, this could provide a way to improve heart function and reduce damage after a heart attack, potentially lowering the risk of heart failure.
- What could go wrong
- This trial is completed but results are not yet widely confirmed. Stem cell therapies can have variable effects, and benefits may be modest or not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
90 people
The number who actually took part.
- Started
-
Sep 2013
- Finished
-
Aug 2024
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
20 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. As of the date of written consent, between 20 and 75 years of age 2. Those with less than 50% of the left ventricular ejection fraction (LVEF) on echocardiography performed after percutaneous coronary intervention (PCI) (evaluated by investigator) 3. Who has been identified as an acute myocardial infarction in any of the following on an electrocardiogram (12-lead electrocardiography, ECG) performed before PCI * ST-segment elevation 0.1 mV in two or more limb leads or * 0.2 mV elevation in two or more contiguous precordial leads indicative of acute myocardial infarction (AMI) 4. Those identified as anterior wall MI 5. Who meet the above criteria and have successfully reperfused within 72 hours after the onset of chest pain 6. Who can conduct clinical trials according to the clinical trial protocol 7. Who has consented in writing to voluntarily participate in this clinical trial (owner or legal representative) Exclusion Criteria: 1. Who have not been diagnosed with malignant blood diseases (acute myelogenous leukemia, acute lymphocytic leukemia, non-Hodgkins lymphoma, Hodgkins lymphoma, multiple myelopathy) within 5 years of screening criteria 2. Patients with severe aplastic anemia 3. Patients with solid cancers in their previous medical history (within 5 years) 4. Patients whose blood serum AST/ASL rates are more than three times the normal maximum rate, and whose creatinine rates are more than 1.5 times the normal maximum rate (but AST in myocardial infarction patients can temporarily rise, thus, as decided by the researchers, if there is no damage to the liver function, the rise will not be taken into consideration) 5. Patients who have implemented Coronary Artery Bypass Graft(CABG) 6. Patients with chronic heart failure (patients with medical history of heart failure medical history at least three months before the occurrence of acute myocardial infarction) 7. Patients who cannot proceed with cardiac catheterization 8. Patients who had been continuously taking large doses of steroids (1mg/kg/day) or antibiotics for severe infections from one month prior to registration 9. Patients who had major surgical operations, organ biopsy, or significant external injury as determined by the researcher, within three months before registration 10. Patients who have head injuries or other external injuries after the development of myocardial infarction 11. patients with stroke or transient ischemic attack within six months before registration, patients with history of central nervous system disease (tumor, aneurysm, brain surgery etc.) 12. Patients with low survival ability after cardiopulmonary resuscitation within last 2 weeks. 13. Patients with positive for HIV, HBV, HCV, Syphilis 14. pregnant women or likely to be pregnant or lactating women 15. Patients with drug abuser within last 1 year. 16. Patients with participating other clinical trials with last 1 month. 17. When the possibility of tumor occurrence is seen when the tester judges even one of the tumor marker tests during screening 18. Who are judged to be inappropriate to participate in this test when judged by the examiner
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute myocardial infarction are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Catholic University of Korea, Seoul ST. Mary's Hospital.
Seoul, South Korea
-
Chonnam National University Hospital
Gwangju, South Korea
-
Chungnam National University Hospital
Jungnam, South Korea
-
Gachon University Gil Medical Center
Incheon, South Korea
-
Inha University Hospital
Incheon, South Korea
-
Kangwon National University Hospital
Chuncheon, South Korea
-
Korea University Medicine
Seoul, South Korea
-
Severance Hospital, Yonsei University College of Medicine
Seoul, South Korea
-
Wonju Severance Christian Hospital
Wŏnju, South Korea
-
Yongin Severance Hospital
Gyeonggi-do, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Every minute counts: study tracks how delays shape heart attack survival
- Stick-On patch aims to catch dangerous heart decline sooner
- Sleep apnea clues may unmask hidden heart risks in survivors
- Can new imaging and genetics unlock the secrets of heart attacks?
- Blood test clues: could two proteins predict heart failure after a heart attack?
- Which strategy wins for heart attack patients with multiple blocked arteries?